Cicely Saunders Institute of Palliative Care (I.J.H., M.H., M.M., K.F.S., A.O.O., R.L.C., S.B.), Policy and Rehabilitation, King's College London, London, UK; King's College Hospital NHS Foundation Trust (I.J.H., K.F.S.), Denmark Hill, UK.
Cicely Saunders Institute of Palliative Care (I.J.H., M.H., M.M., K.F.S., A.O.O., R.L.C., S.B.), Policy and Rehabilitation, King's College London, London, UK.
J Pain Symptom Manage. 2022 Oct;64(4):377-390. doi: 10.1016/j.jpainsymman.2022.06.009. Epub 2022 Jun 23.
Evidence of symptom control outcomes in severe COVID is scant.
To determine changes in symptoms among people severely ill or dying with COVID supported by palliative care, and associations with treatments and survival.
Multicentre cohort study of people with COVID across England and Wales supported by palliative care services, during the pandemic in 2020 and 2021. We analysed clinical, demographic and survival data, symptom severity at baseline (referral to palliative care, first COVID assessment) and at three follow-up assessments using the Integrated Palliative care Outcome Scale - COVID version.
We included 572 patients from 25 services, mostly hospital support teams; 496 (87%) were newly referred to palliative care with COVID, 75 (13%) were already supported by palliative care when they contracted COVID. At baseline, patients had a mean of 2.4 co-morbidities, mean age 77 years, a mean of five symptoms, and were often bedfast or semiconscious. The most prevalent symptoms were: breathlessness, weakness/lack of energy, drowsiness, anxiety, agitation, confusion/delirium, and pain. Median time in palliative care was 46 hours; 77% of patients died. During palliative care, breathlessness, agitation, anxiety, delirium, cough, fever, pain, sore/dry mouth and nausea improved; drowsiness became worse. Common treatments were low dose morphine and midazolam. Having moderate to severe breathlessness, agitation and multimorbidity were associated with shorter survival.
Symptoms of COVID quickly improved during palliative care. Breathlessness, agitation and multimorbidity could be used as triggers for timelier referral, and symptom guidance for wider specialities should build on treatments identified in this study.
严重 COVID 患者的症状控制结果证据有限。
确定在姑息治疗支持下患有 COVID 且病重或病危的患者的症状变化,并确定其与治疗和生存的关联。
2020 年和 2021 年大流行期间,在英格兰和威尔士,对姑息治疗支持下的 COVID 患者进行了一项多中心队列研究。我们分析了临床、人口统计学和生存数据,以及在基线(向姑息治疗团队转诊、首次 COVID 评估)和三个随访评估时使用综合姑息治疗结局量表 - COVID 版本评估的症状严重程度。
我们纳入了来自 25 个服务机构的 572 名患者,其中大多数是医院支持团队;496 名(87%)是新转诊至姑息治疗的 COVID 患者,75 名(13%)在感染 COVID 时已经由姑息治疗团队支持。在基线时,患者平均有 2.4 种合并症,平均年龄 77 岁,平均有 5 种症状,且经常卧床或半昏迷。最常见的症状是:呼吸困难、虚弱/缺乏体力、嗜睡、焦虑、激越、意识混乱/谵妄以及疼痛。姑息治疗中位时间为 46 小时;77%的患者死亡。在姑息治疗期间,呼吸困难、激越、焦虑、谵妄、咳嗽、发热、疼痛、口腔干燥/疼痛以及恶心有所改善;嗜睡恶化。常见的治疗方法是低剂量吗啡和咪达唑仑。中度至重度呼吸困难、激越和多种合并症与较短的生存时间相关。
在姑息治疗期间,COVID 的症状迅速改善。呼吸困难、激越和多种合并症可作为更及时转诊的触发因素,而更广泛的专业领域的症状指导应基于本研究中确定的治疗方法。